These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18691001)

  • 21. Fracture risk is a class effect of glitazones.
    Short R
    BMJ; 2007 Mar; 334(7593):551. PubMed ID: 17363794
    [No Abstract]   [Full Text] [Related]  

  • 22. Managing and maintaining bone mineral density in diabetes patients with pharmacotherapy.
    Fixen CW; Fixen DR
    Expert Opin Pharmacother; 2017 Dec; 18(18):2001-2006. PubMed ID: 29172834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of diabetes drugs on the skeleton.
    Meier C; Schwartz AV; Egger A; Lecka-Czernik B
    Bone; 2016 Jan; 82():93-100. PubMed ID: 25913633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of thiazolidinediones on bone loss and fracture.
    Murphy CE; Rodgers PT
    Ann Pharmacother; 2007 Dec; 41(12):2014-8. PubMed ID: 17940125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bone loss and fracture risk associated with thiazolidinedione therapy.
    Riche DM; King ST
    Pharmacotherapy; 2010 Jul; 30(7):716-27. PubMed ID: 20575635
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of diabetes and diabetes medications on bone health.
    Gilbert MP; Pratley RE
    Endocr Rev; 2015 Apr; 36(2):194-213. PubMed ID: 25738213
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glitazones in type 2 diabetes: an update.
    Drug Ther Bull; 2008 Apr; 46(4):25-9. PubMed ID: 18403615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Thiazolidinediones and fracture risk in patients with Type 2 diabetes.
    Betteridge DJ
    Diabet Med; 2011 Jul; 28(7):759-71. PubMed ID: 21672000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of glucose-lowering drugs and risk of fracture in patients with type 2 diabetes.
    Starup-Linde J; Gregersen S; Frost M; Vestergaard P
    Bone; 2017 Feb; 95():136-142. PubMed ID: 27890548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucose-Lowering Drugs and Fracture Risk-a Systematic Review.
    Al-Mashhadi Z; Viggers R; Fuglsang-Nielsen R; de Vries F; van den Bergh JP; Harsløf T; Langdahl B; Gregersen S; Starup-Linde J
    Curr Osteoporos Rep; 2020 Dec; 18(6):737-758. PubMed ID: 33165875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thiazolidinedione-induced skeletal fragility--mechanisms and implications.
    Grey A
    Diabetes Obes Metab; 2009 Apr; 11(4):275-84. PubMed ID: 18671797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Daily practice using the guidelines for prevention and treatment of osteoporosis. Anti-diabetic agents and fracture risk].
    Okazaki R
    Clin Calcium; 2008 Aug; 18(8):1154-61. PubMed ID: 18677054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The current role of thiazolidinediones in diabetes management.
    Rizos CV; Kei A; Elisaf MS
    Arch Toxicol; 2016 Aug; 90(8):1861-81. PubMed ID: 27165418
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of thiazolidinediones and fracture risk.
    Meier C; Kraenzlin ME; Bodmer M; Jick SS; Jick H; Meier CR
    Arch Intern Med; 2008 Apr; 168(8):820-5. PubMed ID: 18443256
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial.
    Grey A; Bolland M; Fenwick S; Horne A; Gamble G; Drury PL; Reid IR
    Eur J Endocrinol; 2014 Feb; 170(2):255-62. PubMed ID: 24217934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Diabetes mellitus, thiazolidinediones and fractures: an unfinished story].
    Silva AG; Lazaretti-Castro M
    Arq Bras Endocrinol Metabol; 2010 Jun; 54(4):345-51. PubMed ID: 20625645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Diabetes mellitus and osteoporosis. Effect of antidiabetic medicine on osteoporotic fracture].
    Hayakawa N; Suzuki A
    Clin Calcium; 2012 Sep; 22(9):1383-90. PubMed ID: 22932293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rosiglitazone decreases bone mineral density and increases bone turnover in postmenopausal women with type 2 diabetes mellitus.
    Bilezikian JP; Josse RG; Eastell R; Lewiecki EM; Miller CG; Wooddell M; Northcutt AR; Kravitz BG; Paul G; Cobitz AR; Nino AJ; Fitzpatrick LA
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1519-28. PubMed ID: 23450056
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oral anti-diabetic drugs and fracture risk, cut to the bone: safe or dangerous? A narrative review.
    Palermo A; D'Onofrio L; Eastell R; Schwartz AV; Pozzilli P; Napoli N
    Osteoporos Int; 2015 Aug; 26(8):2073-89. PubMed ID: 25910746
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study.
    Bone HG; Lindsay R; McClung MR; Perez AT; Raanan MG; Spanheimer RG
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4691-701. PubMed ID: 24057294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.